ENDO: Novel Male Contraceptive Gel May Achieve Faster Sperm Suppression

2024-06-12
临床结果临床2期
WEDNESDAY, June 12, 2024 -- A novel male contraceptive gel suppresses sperm production faster than other hormone-based methods for male birth control, according to a phase 2 study presented at the annual meeting of the Endocrine Society, held from June 1 to 4 in Boston.
Danielle Gross, from the Eunice Kennedy Shriver National Institute of Child Health and Human Development at the National Institutes of Health in Bethesda, Maryland, and colleagues assessed the time to sperm suppression (concentration ≤1 million/mL) with daily self-administration of segesterone acetate (8 mg)/testosterone (74 mg) combination gel in 222 healthy men.
The researchers found that 86 percent of participants achieved suppression to ≤1 million/mL during treatment. One in five participants (21 percent) were suppressed to ≤1 million/mL at five weeks, which increased to 52 percent by eight weeks and 64 percent by nine weeks. The median time for those achieving suppression was eight weeks, with 82 percent suppressed within 12 weeks and 86 percent at 15 weeks of initiating treatment.
"The development of a safe, highly effective and reliably reversible contraceptive method for men is an unmet need," senior author Diana Blithe, Ph.D., also of the National Institutes of Health, said in a statement. "While studies have shown that some hormonal agents may be effective for male contraception, the slow onset of spermatogenic suppression is a limitation."
Press Release
More Information
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
-
靶点
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。